ReviewBiochemical Society transactions2026
Nitroxoline revisited: antibacterial mechanisms, spectrum, and therapeutic potential of an old drug in the era of antimicrobial resistance.
Review in Biochemical Society transactions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
As the spread of antimicrobial resistance outpaces antibiotic discovery and marketing, there is a critical need to revisit approved compounds with untapped potential. Metal-based complexes (metallo-antimicrobials) represent ideal candidates for such efforts due to their pleiotropic effects, which, unlike antibiotics with single protein targets, may have lower resistance potential. With its well-characterised safety profile, nitroxoline, an 8-hydroxyquinoline derivative, is a prominent compound of this kind. Here, we review recent advances in our understanding of nitroxoline's multimodal mode of action, focusing on its disruption of metal homeostasis at the intracellular and extracellular level. We further explore its clinical utility, including its low propensity for resistance development, and its potential for both combinatorial therapy and as an anti-biofilm agent. Although beyond the scope of the present review, we refer to nitroxoline's antifungal effects whenever they represent a relevant comparison with its antibacterial activity. We highlight current knowledge gaps in nitroxoline's mechanism and in vivo activity that should be bridged to accelerate its repurposing, particularly in the treatment of multidrug-resistant and biofilm-associated infections. Several recent reviews have examined nitroxoline from chemical, clinical, and repurposing perspectives [1, 2, 3, 4]. The present work complements these by providing a mechanistic synthesis of nitroxoline's effects in bacteria, linking its multimodal mode of action to the knowledge gaps that should be addressed before clinical repurposing can proceed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.